Definium's LSD-based depression pill delivers strong late-stage results

- Definium is a biotech startup backed by venture capital, focused on developing psychedelic-based treatments for mental health disorders. It is one of several companies exploring regulated medical use of substances like psilocybin (magic mushrooms), MDMA (ecstasy), and LSD. - The "late-stage trial" is a Phase 3 study — the final human testing phase before a company can seek FDA (U.S. Food and Drug Administration) approval to market the drug. Positive Phase 3 results are a major milestone, but not a guarantee of eventual approval. - LSD (lysergic acid diethylamide) is a powerful hallucinogen that was a target of the U.S. war on drugs in the 1960s-70s and classified as a Schedule I substance (high abuse potential, no accepted medical use). These results signal a potential shift toward reclassifying LSD as a legitimate treatment, though regulatory and cultural hurdles remain. - Current depression treatments (SSRIs like Prozac) often take weeks to work and fail many patients. Psychedelics are being studied as a faster-acting alternative, typically administered in a clinical setting with therapy support — not as a take-home prescription.